This Article Abstract Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jahanzeb, M. Articles by Kronish, L. Search for Related Content PubMed PubMed Citation Articles by Jahanzeb, M. Articles by Kronish, L.

Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2⁺ Metastatic Breast Cancer

^a The Boca Raton Comprehensive Cancer Center, Boca Raton, Florida, USA; ^b Washington University School of Medicine, St. Louis, Missouri, USA; ^c Boston Baskin Cancer Group, Memphis, Tennessee, USA; ^d The Alta Bates Comprehensive Cancer Center, Berkeley, California, USA; ^e New York University School of Medicine, New York, New York, USA; ^f The St. Vincent’s Comprehensive Cancer Center, New York, New York, USA; ^g Michigan Cancer Specialists, Roseville, Michigan, USA

Correspondence: Mohammad Jahanzeb, M.D., Chief, Division of Hematology/Oncology, University of Tennessee College of Medicine, 1331 Union Ave., Suite 800, Memphis, Tennessee 38104, USA. Telephone: 901-255-3132; Fax: 901-255-3134; e-mail: mjahanze{at}utmem.edu

	LEARNING OBJECTIVES

Top Learning Objectives Abstract Introduction Methods Results Discussion References

 
After completing this course, the reader will be able to:

1. Summarize the epidemiology and natural history of HER2⁺ breast cancer.
   
2. Differentiate the two primary methods for measuring HER2 in breast cancer patients.
   
3. Appreciate the rationale for investigating vinorelbine in combination with trastuzumab.
   
4. Discuss the relative efficacy and safety of trastuzumab and vinorelbine in HER2⁺ breast cancer.
   

	ABSTRACT

Top Learning Objectives Abstract Introduction Methods Results Discussion References

 
Purpose. Human epidermal growth factor receptor 2 (HER2) overexpression is associated with a more aggressive form of breast cancer that responds well to trastuzumab therapy. Trastuzumab-based combination regimens have shown greater antitumor activity than chemotherapy alone. These findings, coupled with the favorable antitumor activity and tolerability profile of vinorelbine in breast cancer, provided the rationale for investigating the novel combination of vinorelbine and trastuzumab.

Patients and Methods. A phase II, open-label trial of intravenous vinorelbine (30 mg/m² on day 1, then weekly) and trastuzumab (4 mg/kg on day 0, then 2 mg/kg weekly) was conducted in previously untreated HER2⁺ metastatic breast cancer patients. Vinorelbine dose was adjusted for grade 3/4 neutropenia; patients remained on combination therapy until disease progression or patient withdrawal due to adverse events.

Results. Of 40 enrolled patients (median age 51 years, range 30-82), 37 were evaluable for response. Overall response rate was 78% (29/37, 95% confidence interval [CI] 62%-90%), including four (11%, 95% CI 3%-25%) complete and 25 (68%) partial responses. Objective tumor response correlated with degree of HER2 positivity: immunohistochemistry (IHC) 3⁺ = 82% (18/22) response and IHC 2⁺ = 58% (7/12) response. Median time to progression was 72 weeks (95% CI 37-138 weeks); median survival has not been reached. Grade 3/4 neutropenia was the most frequent serious toxicity and cause of dose reductions (9% of courses) and omissions (10% of courses). No patient experienced serious cardiac toxicity.

Conclusions. Weekly vinorelbine/trastuzumab offers a high therapeutic index as initial therapy in patients with HER2⁺ metastatic breast cancer. Further investigation of this novel regimen is planned.

Key Words. Immunohistochemistry • In situ hybridization • Fluorescence • Breast neoplasms • Neutropenia

	INTRODUCTION

Top Learning Objectives Abstract Introduction Methods Results Discussion References

 
Breast cancer is the second leading cause of cancer-related death (after lung cancer) in women in the U.S. and will comprise approximately 31% of all new cancer cases diagnosed in 2002 [1]. An estimated 203,500 new cases of breast cancer will be diagnosed in 2002, with 39,600 deaths expected [1]. Despite significant improvements in the early diagnosis and treatment of breast cancer and accompanying incremental gains in 5-year survival, a significant number of women will relapse and ultimately die of metastatic disease. Moreover, in the subgroup of breast cancer patients who overexpress human epidermal growth factor receptor 2 (HER2), which comprises 25%-30% of all human breast cancers [2], the disease is particularly virulent and is associated with a greater risk for disease progression and death [2–5]. In this patient subgroup, therapy with alkylating agents or tamoxifen may be proven suboptimal [6, 7], thereby providing the rationale for pursuing novel treatment approaches for the HER2-overexpressing tumor phenotype.

Breast cancers that overexpress the HER2 protein have a unique natural history characterized by high-grade histology, preponderance of estrogen receptor negativity, a greater likelihood of recurrence, and shortened survival. In metastatic breast cancer patients, HER2 overexpression identifies women who are candidates for treatment with the humanized antibody against the extracellular domain of HER2, trastuzumab (Herceptin^®; Genentech, Inc.; South San Francisco, CA). The binding of trastuzumab to HER2 in the presence of peripheral blood mononuclear cells induces antibody-dependent cellular toxicity [8]. Additionally, downregulation of HER2 inhibits tumor cell proliferation, and the role of trastuzumab in causing G₁ arrest may explain, in part, the synergistic antitumor activity observed when administered in combination with chemotherapy.

In patients treated with trastuzumab monotherapy, when HER2 expression was measured by immunohistochemical assays, objective responses were seen in 26% of chemotherapy-naïve patients and 15% of previously treated patients [9–11]. Additionally, trastuzumab administered with either paclitaxel or the combination of doxorubicin and cyclophosphamide significantly improved the objective response rate and prolonged the survival of women with metastatic HER2⁺ breast cancers [12–14]. Unfortunately, the addition of trastuzumab to an anthracycline-based regimen resulted in a more than fourfold increase in cardiac toxicities and one toxic death, attributed to a fatal arrhythmia. Because cardiac toxicity was a concern with some combination regimens, investigators have been interested in combining agents with more favorable safety profiles, among those with demonstrated activity in metastatic breast cancer.

Vinorelbine tartrate (Navelbine^®; GlaxoSmithKline; Philadelphia, PA) is a semisynthetic vinca alkaloid that inhibits tubulin polymerization, thereby impairing the function of mitotic spindles. Vinorelbine is associated with response rates of 35%-50% in first-line treatment of breast cancer and 16%-30% when used in second-line or salvage treatment [15–26]. The primary toxicities associated with vinorelbine are hematologic (i.e., neutropenia) and neuropathic. The reported incidence of cardiac toxicity and alopecia associated with vinorelbine is low, and neurotoxicity is generally mild. Data from in vitro studies have suggested that vinorelbine and trastuzumab are synergistic [27]. Additionally, the results of recent clinical studies have suggested that vinorelbine and trastuzumab may be synergistic [28, 29]. In a single-center feasibility study, Burstein et al. [29] reported an overall response (OR) rate of 75% (95% confidence interval [CI] 57%-89%, with a subset of front-line patients showing an 84% response rate). High antitumor response rates were seen not only in the first-line but also in the second- and third-line settings. Additionally, the toxicity profile of weekly vinorelbine and trastuzumab was favorable and conducive to long-term treatment. The generally mild toxicity profile of vinorelbine and trastuzumab and their activity in metastatic breast cancer patients provided the rationale for this study.

	METHODS

Top Learning Objectives Abstract Introduction Methods Results Discussion References

 
Eligibility
Female patients 18 years of age with microscopically confirmed carcinoma of the breast and HER2 overexpression were enrolled into the study. HER2 overexpression was determined in all patients by immunohistochemistry (IHC), and later, in a subgroup of patients by fluorescence in situ hybridization (FISH).

Patients were required to have bidimensionally measurable disease by physical exam or roentgenographic imaging, Karnofsky performance status of 70% or greater, and a life expectancy of >16 weeks. Patients were ineligible if bone was the only site of measurable disease. Patients could not have received cytotoxic therapy for metastatic disease. However, women who had received adjuvant chemotherapy were considered eligible provided that therapy was completed more than 12 months before study enrollment. Patients who had received radiation therapy and surgery were also eligible provided the interventions had been completed 3 and 2 weeks, respectively, before treatment with weekly vinorelbine and trastuzumab. Patients were required to have a cardiac ejection fraction >50% as measured by multigated radionuclide angiography or echocardiography. Eligible patients demonstrated adequate bone marrow, renal, and hepatic function.

Patients with a medical history of other malignancy within the previous 5 years that might affect the diagnosis of breast cancer, history (<6 months) of myocardial infarction, central nervous system metastases, and clinically significant (grade 2 or worse) peripheral neuropathy were excluded. Patients were required to practice adequate contraception and could not be pregnant or lactating. The Institutional Review Board of participating centers approved the study and all patients provided written informed consent.

Study Design and Treatment Plan
Patients received once-weekly vinorelbine and trastuzumab by intravenous bolus. We chose 28 days (4 weekly doses) as a cycle. Vinorelbine, 30 mg/m², was diluted to a concentration of 1.5 to 3.0 mg/ml in 0.9% saline or 5% dextrose injection and administered into a peripheral or central vein over 6 to 10 minutes. Vinorelbine was administered on days 1, 8, 15, and 22 of each 28-day course. Trastuzumab was given in a loading dose (4.0 mg/kg) on day 0, and subsequently, weekly at 2.0 mg/kg (days 8, 15, and 22). The infusion interval for trastuzumab was set at 90 minutes on day 0, and reduced over subsequent weeks to 30 minutes provided no infusion syndrome was evident. Trastuzumab was administered prior to vinorelbine for all weeks following the initial dose.

Adjustments in the dose of vinorelbine (i.e., 30 mg/m² to 20 mg/m²) were made in patients who experienced grade 3/4 hematologic toxicity, febrile neutropenia, grade 4 neutropenia persisting for 7 days, or grade 4 thrombocytopenia. Hematologic support with G-CSF (Neupogen^®; Amgen Inc.; Thousand Oaks, CA) and recombinant human erythropoietin (PROCRIT^®; Ortho Biotech Products, LP; Raritan, NJ) was applied at the investigator’s discretion. Delays in vinorelbine dosing of 1 week were incurred for grade 3 neutropenia and for grade 2 or higher thrombocytopenia or neurologic toxicity. No adjustments in the dose of trastuzumab were permitted. If serious toxicity persisted for 4 weeks despite dose adjustments or omissions, the patient was taken off the study. Chemotherapy was administered until documented disease progression or unacceptable toxicity.

Study Analysis and Data Handling
Patients who received at least two courses of vinorelbine and trastuzumab were evaluable for efficacy, and patients who received at least one dose were evaluable for toxicity. The antitumor activity of the combination was assessed every 8 weeks by radiologic evaluation or by medical imaging (magnetic resonance imaging, computed tomography scan). Lesions followed by chest x-rays or physical examination were evaluated every 4 weeks. World Health Organization criteria were used to assess antitumor response. Tumor responses were determined by each investigator and subsequently verified at the Boca Raton Cancer Center (there was no central review of radiographic data). Time to progression was defined as the period of time from the first day of treatment to the time when disease progression or relapse was clearly documented. Survival was defined as the interval from the first day of treatment to the date of patient death.

The safety and tolerability of the combination were evaluated by changes in hematologic parameters and other clinical laboratory values, by physical examination, and by the frequency and severity of adverse events. Toxicity was graded according to the revised Cancer Therapy Evaluation Program Common Toxicity Criteria (version 2.0). Serious adverse events included grade 3 hematologic and nonhematologic toxicities. Potential trastuzumab-induced cardiac toxicity was monitored at 3-month intervals or more frequently in patients who experienced an uncomplicated 15% reduction in ejection fraction while receiving trastuzumab therapy.

All data are presented as the mean or median. The primary end point was overall tumor response, which was composed of complete and partial responses. The 95% CIs were determined for response rates and time to progression. Time to progression and overall survival were estimated using the Kaplan-Meier method.

	RESULTS

Top Learning Objectives Abstract Introduction Methods Results Discussion References

 
Patient Characteristics and Disposition
Forty women were enrolled in the trial between March 1999 and May 2001. The characteristics of this patient population are summarized in Table 1. The median age was 51 years (range 30 to 82), and 95% of patients had Karnofsky performance status 80 at study entry. HER2 protein overexpression was determined by IHC in 39 women and by FISH alone in one. Tumor specimens from 24 patients were retrospectively subjected to FISH. Seventeen (44%) patients had tumors that overexpressed HER2 weakly (2⁺), and in 22 (56%), the overexpression was 3⁺. In 25 patients where FISH analysis was available, 12 of the tumors had 2⁺ overexpression by IHC and only one was positive by FISH. All but one of the 3⁺ staining tumors by IHC were positive by FISH. The majority of patients (72%) had received adjuvant therapy, with patients evenly divided among those who received chemotherapy and hormone therapy. Most patients presented with two sites of metastases.

Antitumor Response
Thirty-seven patients were evaluable for tumor response, and 40 were evaluable for toxicity. Of the three unevaluable patients, one was diagnosed with tuberculosis during the first course, one died of sepsis (unrelated to neutropenia) during the first course, and one was taken off study after the first course after it was found that she was FISH^-. The antitumor response to weekly vinorelbine and trastuzumab is summarized in Table 2. The intent-to-treat OR rate was 72%. The OR rate was 78% (95% CI 62%-90%), including four (11%, 95% CI 3%-25%) complete responses (CRs) and 25 (68%) partial responses (PRs). Four (11%) patients exhibited stable disease, the durations of which were 4, 12, 21, and 122 weeks. Finally, four (11%) patients progressed.

View larger version (8K): [in this window] [in a new window]   Figure 1. Time to progression (dotted line) and overall survival (solid line).

The nonhematologic safety profile of weekly vinorelbine and trastuzumab was mild and favorable (Table 5). No patient was hospitalized as a result of this toxicity. There were three cases of grade 3 neuropathy that led to vinorelbine dose reductions. Neuropathy rarely (n = 2 events) led to dose omissions. No other nonhematologic toxicity was associated with dose reductions or omissions. All but one infusion-site reactions were mild, and all were resolved following intravenous access device placement. No patient experienced a serious infusion syndrome related to trastuzumab treatment. One grade 4 nonhematologic toxicity (fatigue) was observed. There was one case of grade 2 cardiac toxicity evidenced by a decreased ejection fraction of >20% but <24%; the patient was asymptomatic and remained on study until progression of disease. There was no grade 3 or 4 cardiac toxicity, and no patient discontinued trastuzumab therapy because of cardiac toxicity. Finally, no patient died as a result of complications related to treatment with vinorelbine and trastuzumab.

	DISCUSSION

Top Learning Objectives Abstract Introduction Methods Results Discussion References

The addition of vinorelbine to trastuzumab therapy appears to improve the OR rates up to threefold compared with either one alone in HER2-overexpressing metastatic breast cancer patients [29]. The OR rate observed in this trial (78%, 95% CI 62%-92%) was at least comparable with that reported by Burstein et al. from their multicenter trial with vinorelbine/trastuzumab (64%, 95% CI 49%-77%) [28] despite the large number of patients accrued in our trial who were HER2⁺/FISH^-. In contrast, patients enrolled in the multicenter Burstein et al. trial were required to have HER2⁺ tumors by FISH⁺ or IHC 3⁺.

Other trastuzumab-based regimens have been of interest to investigators, including novel combinations with taxanes. Although a direct comparison of response rates among regimens used in different trials is problematic due to differences in selected patients, number and type of prior treatments, and HER2 testing methodologies, the response rates achieved with weekly vinorelbine and trastuzumab are comparable with the best responses observed with other more toxic combination regimens [12, 30]. In a recent study by Esteva et al. [30], the OR rate in patients receiving weekly docetaxel and trastuzumab therapy was 63% (19/30). In that trial, the majority (24/28) had HER2⁺ tumors by FISH and had received prior chemotherapy. Similarly, the activity of trastuzumab and paclitaxel has been established in previously treated metastatic breast cancer patients [12]. The efficacy and tolerability of trastuzumab-based therapy with docetaxel and carboplatin have also been reported [31]. In that study, among 14 FISH⁺ patients, there were two CRs and seven PRs for an OR rate of 64%. A similar study of trastuzumab and docetaxel with cisplatin administered in first-line metastatic breast cancer patients reported an OR rate of 76% (26/34) [32]. That study enrolled patients who were IHC 2⁺ or 3⁺. Finally, trastuzumab-based combination therapy with gemcitabine has been evaluated in previously treated HER2⁺ metastatic breast cancer patients, with early success (PR rate of 32%) [33].

In addition to improving OR rates, vinorelbine and trastuzumab extended the time to disease progression compared with historical data of trastuzumab used as single-agent therapy. Similar to our tumor response findings, the time to progression of patients receiving vinorelbine and trastuzumab compared favorably with the best durations reported with other metastatic breast cancer treatments.

In this study, although involving small subsets of patients, there was a suggestion that HER2 status correlated with tumor response. Patients with tumors that were IHC 3⁺ exhibited a higher response rate (82%) than those with tumors that were weakly positive or IHC 2⁺ (58%). These data are consistent with the Burstein et al. study [29] in which 80% of HER2 3⁺ and 60% of HER2 2⁺ patients achieved tumor responses. Furthermore, all but one IHC 3⁺ overexpressing tumors tested positive for HER2 gene amplification by FISH (n = 11). Weaker IHC overexpression signals were not associated with HER2 gene amplification. Of the 12 patients exhibiting tumors that were IHC 2⁺, only one was FISH⁺. These findings are consistent with those reported by Seidman et al. [14], in which the antibody used in the IHC test may have had a lower specificity for HER2, thereby leading to a potential overestimation of HER2 positivity, or, alternatively, the reporting of a higher frequency of false positives. Additionally, because tumor response to trastuzumab therapy has been shown to correlate with HER2 positivity [14, 29], treatment of patients with nonamplified HER2 levels may under-report the true efficacy via the treatment of patients who are less likely to derive benefits. Nonetheless, greater overexpression or amplification of HER2 by either IHC or FISH was associated with higher response rates.

Another important aspect of treating patients with metastatic breast cancer is the selection of a regimen that is well tolerated and does not affect quality of life. Although quality of life was not assessed in the current study, weekly vinorelbine and trastuzumab treatment was generally well tolerated. The combination was associated with a favorable symptom profile that included mild (grade 1) neuropathy, gastrointestinal effects, and no significant alopecia. In contrast, 29% of patients receiving paclitaxel and trastuzumab experienced grade 3/4 neuropathy [14]. Additionally, the worst cardiac toxicity associated with weekly vinorelbine and trastuzumab involved one case of grade 2 cardiac toxicity. These data are consistent with those previously reported with vinorelbine and trastuzumab therapy [29]. Although patients should be monitored for cardiac toxicity while on trastuzumab therapy, vinorelbine does not appear to enhance trastuzumab-induced cardiac toxicity. The incidence of cardiac toxicity (<1% of courses) seen in our study was consistent with that expected with the use of trastuzumab as single-agent therapy in patients who have not received prior treatment with doxorubicin [34]. By contrast, the addition of paclitaxel and doxorubicin to trastuzumab has been associated with a higher incidence of serious cardiac toxicity, including life-threatening toxicity [12, 14, 34].

As expected with the use of vinorelbine, the most common serious toxicity was grade 3/4 neutropenia. Hematologic toxicity was managed by adjustments in the dose of vinorelbine and delays in administering subsequent doses when warranted. No adjustments in the dose of trastuzumab were required because of hematologic toxicity. Finally, no patient died of a complication related to hematologic toxicity.

In summary, the results of this study support the continued development of weekly vinorelbine and trastuzumab in patients with HER2⁺ metastatic breast cancer. The response rates observed in this trial were comparable with the previous single-center trial using this combination and continue to demonstrate the superiority of the combination over therapy with either agent alone. Additionally, the incorporation of vinorelbine in this combination regimen yielded a very favorable toxicity profile. There was a significant reduction in the incidence of alopecia and neurotoxicity relative to that observed with other combination regimens, such as paclitaxel and trastuzumab. The majority of patients were able to remain on therapy at or near the recommended doses in an outpatient setting, with little disruption in the administration of subsequent courses. Additionally, the favorable toxicity profile and high antitumor activity of weekly vinorelbine and trastuzumab may translate into improvements in the quality of life of patients with HER2⁺ metastatic breast cancer. In conclusion, weekly vinorelbine/trastuzumab offers a high therapeutic index as initial therapy in patients with HER2⁺ metastatic breast cancer. Further investigation of this novel regimen in comparison with docetaxel/ trastuzumab in a randomized multicenter study is ongoing.

	ACKNOWLEDGMENT

Top Learning Objectives Abstract Introduction Methods Results Discussion References

 
The authors thank the many investigators and participating sites, including Alan B. Astrow, M.D., at The St. Vincent’s Comprehensive Cancer Center, Generosa Grana, M.D., at Cooper Hospital/University Medical Center, Rafat Ansari, M.D., at Michigan Hematology Oncology PC, Carol J. Fabian, M.D., at The University of Kansas Medical Center, and Alexander E. Denes, M.D., at Washington University School of Medicine. The authors also thank the study nurse coordinators, including Beth Davis, C.R.A., Steve West, R.N., Pat McLaughin, R.N., Rebecca Clark-Snow, R.N., Mary Jean Wasielewski, R.N., Michelle Cordner, R.N., Tawnie Thomas, R.N., and Alethea Paradis, R.N. Finally, we thank the patients and administrative assistants for their participation and assistance, respectively.

	REFERENCES

Top Learning Objectives Abstract Introduction Methods Results Discussion References

 

1. Jemal A, Thomas A, Murray T et al. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23–47.[Abstract/Free Full Text]
2. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707–712.[Abstract/Free Full Text]
3. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2-2/neu oncogene. Science 1987;235:177–182.[Abstract/Free Full Text]
4. Seshadri R, Firgaira FA, Horsfall DJ et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993;11:1936–1942.[Abstract/Free Full Text]
5. Berns EM, Klijn JG, van Putten WL et al. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res 1992;52:1107–1113.[Abstract/Free Full Text]
6. Ravdin PM, Green S, Albain KS et al. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with Tamoxifen (T) alone. Proc Am Soc Clin Oncol 1998;17:97a.
7. Bianco AR, De Laurentiis M, Carlomagno C et al. 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: evidence of interaction between c-Erb-B2 expression and tamoxifen efficacy. Proc Am Soc Clin Oncol 1998;17:97a.
8. Shepard HM, Lewis GD, Sarup JC et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 1991;11:117–127.[CrossRef][Medline]
9. Bell R. Ongoing trials with trastuzumab in metastatic breast cancer. Ann Oncol 2001;12(suppl 1):S69–S73.[Abstract]
10. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719–726.[Abstract/Free Full Text]
11. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639–2648.[Abstract/Free Full Text]
12. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–792.[Abstract/Free Full Text]
13. Eiermann W. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann Oncol 2001;12(suppl 1):S57–S62.
14. Seidman AD, Fornier MN, Esteva FJ et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587–2595.[Abstract/Free Full Text]
15. Canobbio L, Boccardo F, Pastorino G et al. Phase-II study of Navelbine in advanced breast cancer. Semin Oncol 1989;16(suppl 4):33–36.[Medline]
16. Fumoleau P, Delgado FM, Delozier T et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993;11:1245–1252.[Abstract/Free Full Text]
17. Romero A, Rabinovich MG, Vallejo CT et al. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 1994;12:336–341.[Abstract]
18. Degardin M, Bonneterre J, Hecquet B et al. Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 1994;5:423–426.[Abstract/Free Full Text]
19. Twelves CJ, Dobbs NA, Curnow A et al. A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer 1994;70:990–993.[Medline]
20. Gasparini G, Caffo O, Barni S et al. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol 1994;12:2094–2101.[Abstract/Free Full Text]
21. Garcia-Conde J, Lluch A, Martin M et al. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 1994;5:854–857.[Abstract/Free Full Text]
22. Barni S, Ardizzoia A, Bernardo G et al . Vinorelbine as single agent in pretreated patients with advanced breast cancer. Tumori 1994;80:280–282.[Medline]
23. Weber BL, Vogel C, Jones S et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 1995;13:2722–2730.[Abstract]
24. Jones S, Winer E, Vogel C et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995;13:2567–2574.[Abstract]
25. Ibrahim NK, Rahman Z, Valero V et al. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer 1999;86:1251–1257.[CrossRef][Medline]
26. Vogel C, O’Rourke M, Winer E et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 1999;10:397–402.[Abstract/Free Full Text]
27. Konecny G, Pegram MD, Beryt M et al. Therapeutic advantage of chemotherapy drugs in combination with Herceptin^® against human breast cancer cells with HER-2/neu overexpression. Breast Cancer Res Treat 1999;57:114.
28. Burstein HJ, Marcom PK, Lambert-Falls R et al. Multicenter phase II study of trastuzumab (herceptin; H) and vinorelbine (navelbine; N) as first-line therapy for HER2 overexpressing metastatic breast cancer (HER2⁺ MBC). Proc Am Soc Clin Oncol 2002;21:53a.
29. Burstein HJ, Kuter I, Campos SM et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19:2722–2730.[Abstract/Free Full Text]
30. Esteva FJ, Valero V, Booser D et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2–overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800–1808.[Abstract/Free Full Text]
31. Slamon DJ, Patel R, Northfelt R et al. Phase II pilot study of herceptin combined with taxotere and carboplatin (TCH) in metastatic breast cancer (MBC) patients overexpressing the HER2-Neu proto-oncogene: a pilot study of the UCLA network. Proc Am Soc Clin Oncol 2001;20:49a.
32. Pienkowski T, Fumoleau P, Eirmann W et al. Taxotere, cisplatin and herceptin (TCH) in first-line HER2 positive metastatic breast cancer (MBC) patients, a phase II pilot study by the Breast Cancer International Research Group (BCIRG 101). Proc Am Soc Clin Oncol 2001;20:120b.
33. O’Shaughnessy JA, Vukelja S, Marsland T et al. Gemcitabine and trastuzumab for HER-2 positive metastatic breast cancer: preliminary results of a phase II study. Program and Abstract of the 24th Annual San Antonio Breast Cancer Symposium. December 10-13, 2001, San Antonio, Texas. Abstract 523.
34. Sparano JA. Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. Semin Oncol 2001;28(suppl 3):20–27.

This article has been cited by other articles:

				S. Beslija, J. Bonneterre, H. J. Burstein, V. Cocquyt, M. Gnant, V. Heinemann, J. Jassem, W. J. Kostler, M. Krainer, S. Menard, et al. Third consensus on medical treatment of metastatic breast cancer Ann. Onc., November 1, 2009; 20(11): 1771 - 1785. [Abstract] [Full Text] [PDF]

				A. Chan and R. de Boer Use of Trastuzumab for Metastatic Breast Cancer in Australia: Inaccurate Results and Alternative Interpretation of Findings J. Clin. Oncol., December 10, 2007; 25(35): 5662 - 5663. [Full Text] [PDF]

				C. Catania, M. Medici, E. Magni, E. Munzone, D. Cardinale, L. Adamoli, G. Sanna, I. Minchella, D. Radice, A. Goldhirsch, et al. Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination Ann. Onc., December 1, 2007; 18(12): 1969 - 1975. [Abstract] [Full Text] [PDF]

				C. A. Hudis Trastuzumab -- Mechanism of Action and Use in Clinical Practice N. Engl. J. Med., July 5, 2007; 357(1): 39 - 51. [Full Text] [PDF]

				A Chan A review of the use of trastuzumab (Herceptin(R)) plus vinorelbine in metastatic breast cancer Ann. Onc., July 1, 2007; 18(7): 1152 - 1158. [Abstract] [Full Text] [PDF]

				S. A. Limentani, A. M. Brufsky, J. K. Erban, M. Jahanzeb, and D. Lewis Phase II Study of Neoadjuvant Docetaxel, Vinorelbine, and Trastuzumab Followed by Surgery and Adjuvant Doxorubicin Plus Cyclophosphamide in Women With Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancer J. Clin. Oncol., April 1, 2007; 25(10): 1232 - 1238. [Abstract] [Full Text] [PDF]

				M. Colozza, E. de Azambuja, N. Personeni, F. Lebrun, M. J. Piccart, and F. Cardoso Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer Oncologist, March 1, 2007; 12(3): 253 - 270. [Abstract] [Full Text] [PDF]

				L. N. Harris, F. You, S. J. Schnitt, A. Witkiewicz, X. Lu, D. Sgroi, P. D. Ryan, S. E. Come, H. J. Burstein, B.-A. Lesnikoski, et al. Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer Clin. Cancer Res., February 15, 2007; 13(4): 1198 - 1207. [Abstract] [Full Text] [PDF]

				S Beslija, J Bonneterre, H Burstein, V Cocquyt, M Gnant, P Goodwin, V Heinemann, J Jassem, W. Kostler, M Krainer, et al. Second consensus on medical treatment of metastatic breast cancer Ann. Onc., February 1, 2007; 18(2): 215 - 225. [Abstract] [Full Text] [PDF]

				C. Jackisch HER-2-Positive Metastatic Breast Cancer: Optimizing Trastuzumab-Based Therapy Oncologist, September 1, 2006; 11(suppl_1): 34 - 41. [Abstract] [Full Text] [PDF]

				P. Papaldo, A. Fabi, G. Ferretti, M. Mottolese, A. M. Cianciulli, B. Di Cocco, M. S. Pino, P. Carlini, S. Di Cosimo, I. Sacchi, et al. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease Ann. Onc., April 1, 2006; 17(4): 630 - 636. [Abstract] [Full Text] [PDF]

				M. Marty, F. Cognetti, D. Maraninchi, R. Snyder, L. Mauriac, M. Tubiana-Hulin, S. Chan, D. Grimes, A. Anton, A. Lluch, et al. Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group J. Clin. Oncol., July 1, 2005; 23(19): 4265 - 4274. [Abstract] [Full Text] [PDF]

				M. Toi, T. Saeki, K. Aogi, M. Sano, K. Hatake, T. Asaga, Y. Tokuda, S. Mitsuyama, M. Kimura, T. Kobayashi, et al. Late Phase II Clinical Study of Vinorelbine Monotherapy in Advanced or Recurrent Breast Cancer Previously Treated with Anthracyclines and Taxanes Jpn. J. Clin. Oncol., June 1, 2005; 35(6): 310 - 315. [Abstract] [Full Text] [PDF]

				A. Hamilton and G. Hortobagyi Chemotherapy: What Progress in the Last 5 Years? J. Clin. Oncol., March 10, 2005; 23(8): 1760 - 1775. [Full Text] [PDF]

				C. Bernard-Marty, F. Cardoso, and M. J. Piccart Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer Oncologist, November 1, 2004; 9(6): 617 - 632. [Abstract] [Full Text] [PDF]

				B. Leyland-Jones, K. Gelmon, J.-P. Ayoub, A. Arnold, S. Verma, R. Dias, and P. Ghahramani Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel J. Clin. Oncol., November 1, 2003; 21(21): 3965 - 3971. [Abstract] [Full Text] [PDF]

				H. J. Burstein, L. N. Harris, P. K. Marcom, R. Lambert-Falls, K. Havlin, B. Overmoyer, R. J. Friedlander Jr., J. Gargiulo, R. Strenger, C. L. Vogel, et al. Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm J. Clin. Oncol., August 1, 2003; 21(15): 2889 - 2895. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jahanzeb, M. Articles by Kronish, L. Search for Related Content PubMed PubMed Citation Articles by Jahanzeb, M. Articles by Kronish, L.